Investigational drug · Phase 3
Exendin-4 Fc fusion protein
Also called: JY09
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type2 Diabetes Mellitus, Type 2 Diabetes Mellitus.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Exendin-4 Fc fusion protein"
First trial start
2024
Jul 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Exendin-4 Fc fusion protein", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type2 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Exendin-4 Fc fusion protein" as an intervention, largest first.
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminPivotal-lookingActive, not recruiting
Beijing Dongfang Biotech Co., Ltd.Industry
NCT06257966 · 600 participants · Start Jul 17, 2024 · Primary completion Oct 1, 2026
Drug: Exendin-4 Fc fusion protein injection(1.2mg); Exendin-4 Fc fusion protein injection(2.4mg) and 2 more · For: Type2 Diabetes Mellitus
Sites: Beijing, China
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM PatientsPivotal-lookingActive, not recruiting
Beijing Dongfang Biotech Co., Ltd.Industry
NCT06254014 · 270 participants · Start Jul 10, 2024 · Primary completion May 1, 2026
Drug: Exendin-4 Fc fusion protein injection; Exendin-4 Fc fusion protein injection and 1 more · For: Type 2 Diabetes Mellitus
Sites: Beijing, China
Beijing Dongfang Biotech Co., Ltd.Industry
NCT06247748 · 28 participants · Start Oct 19, 2023 · Primary completion Apr 15, 2024
Drug: Exendin-4 Fc fusion protein (JY09) injection; Metformin Hydrochloride tablet and 2 more · For: Diabetes Mellitus, Type 2; Overweight
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study.
Yang G, Cao B, Yang Y, et al. · Int J Clin Pharmacol Ther 2020
Also in development for Type2 Diabetes Mellitus
- AleniglipronPhase 36 trials
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.